Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
作者信息
Bollard Catherine M, Gottschalk Stephen, Helen Huls M, Leen Ann M, Gee Adrian P, Rooney Cliona M
机构信息
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA.
出版信息
Cytotherapy. 2011 May;13(5):518-22. doi: 10.3109/14653249.2011.561983. Epub 2011 Mar 1.
Abstract
摘要
相似文献
1
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.用于爱泼斯坦-巴尔病毒相关淋巴瘤患者的、针对潜伏膜蛋白（LMP）-1和LMP2的药品生产质量管理规范级细胞毒性T淋巴细胞。
Cytotherapy. 2011 May;13(5):518-22. doi: 10.3109/14653249.2011.561983. Epub 2011 Mar 1.
2
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.接受针对 Epstein-Barr 病毒潜伏膜蛋白的自体细胞毒性 T 淋巴细胞治疗的淋巴瘤患者获得持续完全缓解。
J Clin Oncol. 2014 Mar 10;32(8):798-808. doi: 10.1200/JCO.2013.51.5304. Epub 2013 Dec 16.
3
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.肿瘤抗原呈递细胞基因改造及T淋巴细胞转移后复发淋巴瘤的完全缓解
Blood. 2007 Oct 15;110(8):2838-45. doi: 10.1182/blood-2007-05-091280. Epub 2007 Jul 3.
4
Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.用自体淋巴母细胞系和LMP2衍生的、HLA - A24限制性9肽在体外诱导的细胞毒性T淋巴细胞对爱泼斯坦-巴尔病毒相关胃癌细胞的识别
Oncol Rep. 2004 Oct;12(4):725-31.
5
EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.用于EBV相关淋巴瘤的EBV定向T细胞疗法
Methods Mol Biol. 2017;1532:255-265. doi: 10.1007/978-1-4939-6655-4_19.
6
Targeting Epstein-Barr virus-associated lymphomas.
J Clin Oncol. 2014 Mar 10;32(8):830-2. doi: 10.1200/JCO.2013.53.2994. Epub 2014 Feb 3.
7
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.用于从复发的EBV阳性霍奇金病患者进行过继性转移的LMP2特异性CTL的产生及特性分析
J Immunother. 2004 Jul-Aug;27(4):317-27. doi: 10.1097/00002371-200407000-00008.
8
Latent membrane protein-specific cytotoxic T lymphocytes: new hope for patients with natural killer/T-cell lymphoma?
J Clin Oncol. 2014 Sep 1;32(25):2819-20. doi: 10.1200/JCO.2014.56.3551. Epub 2014 Jul 21.
9
Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.异基因爱泼斯坦-巴尔病毒（EBV）特异性细胞毒性T淋巴细胞用于难治性EBV相关淋巴瘤患者的安全性
Br J Haematol. 2002 Sep;118(3):799-808. doi: 10.1046/j.1365-2141.2002.03683.x.
10
EBV-associated lymphomas in adults.成人 EBV 相关淋巴瘤。
Best Pract Res Clin Haematol. 2012 Mar;25(1):75-89. doi: 10.1016/j.beha.2012.01.005. Epub 2012 Feb 5.
引用本文的文献
1
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.抗病毒细胞治疗增强造血干细胞移植前后 T 细胞重建（ACES）：评估危险因素的儿科患者的两臂、开放标签、二期干预性试验。
Nat Commun. 2024 Apr 18;15(1):3258. doi: 10.1038/s41467-024-47057-2.
2
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.利妥昔单抗和第三方 LMP 特异性 T 细胞治疗后对 EBV 的持久免疫力：一项儿童肿瘤学组研究。
Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832.
3
Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies.用于制造过继性细胞免疫疗法的生物反应器开发的最新进展
Bioengineering (Basel). 2022 Dec 15;9(12):808. doi: 10.3390/bioengineering9120808.
4
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.针对癌症和病毒相关疾病的抗原特异性 T 细胞疗法的产生和应用。
Mol Ther. 2022 Jun 1;30(6):2130-2152. doi: 10.1016/j.ymthe.2022.02.002. Epub 2022 Feb 9.
5
EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.EBV+ 淋巴增殖性疾病：利用 EBV 作为治疗靶点的机会。
Blood. 2022 Feb 17;139(7):983-994. doi: 10.1182/blood.2020005466.
6
Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy.使用细胞因子分析进行 T 细胞表型分析，以改进 EBV 特异性 T 细胞治疗的生产。
Clin Exp Immunol. 2021 Oct;206(1):68-81. doi: 10.1111/cei.13640. Epub 2021 Jul 14.
7
Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.生物反应器中的淋巴细胞扩增：提升过继性细胞疗法
J Biol Eng. 2021 Apr 13;15(1):13. doi: 10.1186/s13036-021-00264-7.
8
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.异基因骨髓移植后，EBV/LMP 特异性 T 细胞可维持 T 和 B 细胞 EBV 淋巴瘤的缓解。
Blood. 2018 Nov 29;132(22):2351-2361. doi: 10.1182/blood-2018-07-863654. Epub 2018 Sep 27.
9
Optimizing the production of suspension cells using the G-Rex "M" series.利用 G-Rex"M"系列优化悬浮细胞的生产。
Mol Ther Methods Clin Dev. 2014 May 14;1:14015. doi: 10.1038/mtm.2014.15. eCollection 2014.
10
Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.抗原呈递细胞的互补作用，以产生具有广泛靶特异性的 T 淋巴细胞。
J Immunother. 2014 May;37(4):193-203. doi: 10.1097/CJI.0000000000000014.
本文引用的文献
1
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).使用透气快速扩增培养器（G-Rex）加速用于临床前和临床应用的抗原特异性 T 细胞的生产。
J Immunother. 2010 Apr;33(3):305-15. doi: 10.1097/CJI.0b013e3181c0c3cb.
2
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.肿瘤抗原呈递细胞基因改造及T淋巴细胞转移后复发淋巴瘤的完全缓解
Blood. 2007 Oct 15;110(8):2838-45. doi: 10.1182/blood-2007-05-091280. Epub 2007 Jul 3.
3
Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.接触激活的单核细胞：用于刺激抗原特异性T细胞的高效抗原呈递细胞。
J Immunother. 2007 Jan;30(1):96-107. doi: 10.1097/01.cji.0000211325.30525.84.
4
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.针对爱泼斯坦-巴尔病毒阳性霍奇金淋巴瘤的细胞毒性T淋巴细胞疗法。
J Exp Med. 2004 Dec 20;200(12):1623-33. doi: 10.1084/jem.20040890.
5
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.用于从复发的EBV阳性霍奇金病患者进行过继性转移的LMP2特异性CTL的产生及特性分析
J Immunother. 2004 Jul-Aug;27(4):317-27. doi: 10.1097/00002371-200407000-00008.
6
Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.利用淋巴母细胞系大规模扩增树突状细胞致敏的多克隆人细胞毒性T淋巴细胞系用于过继性免疫治疗
J Immunother. 2003 May-Jun;26(3):241-56. doi: 10.1097/00002371-200305000-00008.
7
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.产生针对EB病毒次要LMP1抗原的细胞毒性T淋巴细胞用于EB病毒相关恶性肿瘤的过继性免疫治疗。
Blood. 2003 Mar 1;101(5):1905-12. doi: 10.1182/blood-2002-05-1514. Epub 2002 Oct 31.
8
9
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.生产用于过继转移至患EB病毒相关淋巴增殖性疾病高风险患者的转基因爱泼斯坦-巴尔病毒特异性细胞毒性T细胞。
J Hematother. 1995 Apr;4(2):73-9. doi: 10.1089/scd.1.1995.4.73.
10
Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.转化的狨猴白细胞释放传染性爱泼斯坦-巴尔病毒。
Proc Natl Acad Sci U S A. 1973 Jan;70(1):190-4. doi: 10.1073/pnas.70.1.190.
Zotero 插件